3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
105
Gynecologic
6
Thoracic
2
Gastrointestinal
2
Endocrine
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Classical hematology
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
7
Therapeutics
6
Flow Cytometry
6
Radiotherapy
4
Peripheral Blood Stem Cell Transplantation
4
Filgrastim
4
Psychiatric Rehabilitation
3
Polymerase Chain Reaction
3
Paclitaxel
3
Immunologic Techniques
3
Immunoenzyme Techniques
3
Doxorubicin
3
Carboplatin
3
Amplified Fragment Length Polymorphism Analysis
3
venetoclax
2
trametinib
2
temsirolimus
2
sargramostim
2
ruxolitinib
2
pertuzumab
2
pembrolizumab
2
palbociclib
2
liposomal doxorubicin
2
liposomal amphotericin B
2
dabrafenib
2
copanlisib
2
bosutinib
2
aldesleukin
2
abiraterone
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
ribociclib
×
Other hematologic neoplasm
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts